OpenAI acquires Orchestra Bio to boost drug development

OpenAI has acquired Orchestra Bio, a platform that helps biopharmaceutical companies coordinate drug development. The acquisition integrates Orchestra Bio's tools with OpenAI's Rosalind AI suite for life sciences. The combined platform aims to help scientists manage complex drug development workflows, from research to clinical trials, potentially reducing the average 10-15 year timeline to bring medicines to market.